• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

T1 期膀胱尿路上皮癌的预后因素:记录浸润毫米深度、浸润性癌直径和黏膜肌层浸润的价值。

Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion.

机构信息

Department of Pathology, McGill University Health Center, Quebec, Canada H3G 1A4.

出版信息

Hum Pathol. 2013 Jan;44(1):95-102. doi: 10.1016/j.humpath.2012.04.020. Epub 2012 Aug 30.

DOI:10.1016/j.humpath.2012.04.020
PMID:22939956
Abstract

pT1 bladder urothelial carcinomas represent a heterogeneous group of tumors with different biologic behaviors, and identifying the subset of tumors that carries a high risk of disease recurrence and progression is therefore important. We evaluated the prognostic significance of substaging 86 cases of pT1 bladder urothelial carcinoma based on different pathologic parameters. The mean tumor depth was 1.1 mm, and the mean diameter of the invasive focus was 2.2 mm. The mean number of tissue fragments with invasion was 4.4. Lymphovascular invasion and concomitant carcinoma in situ were present in 13% and 45% of cases, respectively. Although 56% of patients recurred, 18% experienced disease progression. Multivariate analysis showed a significant association between muscularis mucosa invasion (P = .007), depth of invasion (P = .0001), diameter of invasive focus (P = .014), and progression. Furthermore, depth of invasion more than 3 mm was significantly associated with progression of disease, achieving a sensitivity of 31%, specificity of 99%, and predictive value of 79%. In comparison, the cutoff values for the diameter of invasive carcinoma that correlated best with outcome was 6 mm for progression. Lastly, combining both variables showed a strong prognostic accuracy where it predicted 94% of recurrences. Importantly, all cases with depth of invasion more than 3 mm and diameter more than 6 mm progressed. Lymphovascular invasion or concomitant carcinoma in situ did not correlate with outcome. From the current data, we do recommend reporting muscularis mucosa invasion whenever possible. Alternatively, tumor depth and tumor diameter should be included in the final pathology report in individual cases in which muscularis mucosa invasion cannot be assessed.

摘要

pT1 膀胱尿路上皮癌是一组具有不同生物学行为的异质性肿瘤,因此确定具有高疾病复发和进展风险的肿瘤亚组非常重要。我们评估了基于不同病理参数的 86 例 pT1 膀胱尿路上皮癌的亚分期对预后的影响。肿瘤平均深度为 1.1mm,侵袭灶的平均直径为 2.2mm。平均有 4.4 个组织碎片有侵袭。13%的病例存在脉管侵犯,45%的病例存在同时性原位癌。尽管 56%的患者复发,但有 18%的患者发生疾病进展。多因素分析显示黏膜肌层侵犯(P=.007)、浸润深度(P=.0001)、侵袭灶直径(P=.014)与进展显著相关。此外,浸润深度超过 3mm 与疾病进展显著相关,其敏感性为 31%,特异性为 99%,预测值为 79%。相比之下,与结果相关性最佳的侵袭性膀胱癌直径的截断值为 6mm,用于进展。最后,联合这两个变量显示出很强的预后准确性,预测了 94%的复发。重要的是,所有浸润深度超过 3mm 且直径超过 6mm 的病例均进展。脉管侵犯或同时性原位癌与结局无关。根据目前的数据,我们建议在可能的情况下报告黏膜肌层侵犯。或者,在无法评估黏膜肌层侵犯的情况下,肿瘤深度和肿瘤直径应包含在最终的病理报告中。

相似文献

1
Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion.T1 期膀胱尿路上皮癌的预后因素:记录浸润毫米深度、浸润性癌直径和黏膜肌层浸润的价值。
Hum Pathol. 2013 Jan;44(1):95-102. doi: 10.1016/j.humpath.2012.04.020. Epub 2012 Aug 30.
2
Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.在非肌肉浸润性膀胱癌中鉴别黏膜肌层浸润(T1a 与 T1b)的预后意义:法国全国多中心研究及中心病理复查。
J Urol. 2013 Jun;189(6):2069-76. doi: 10.1016/j.juro.2012.11.120. Epub 2012 Nov 28.
3
Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients.初发高级别T1期尿路上皮癌:卡介苗治疗和未治疗患者中固有层浸润微分期(T1a/b/c)的可行性及预后意义
Eur Urol. 2005 Aug;48(2):231-8; discussion 238. doi: 10.1016/j.eururo.2005.04.013.
4
The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma.黏膜肌层浸润和p53过表达对T1期膀胱癌进展的预测价值。
J Urol. 2001 Jan;165(1):42-6; discussion 46. doi: 10.1097/00005392-200101000-00011.
5
Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.经尿道切除标本中的淋巴管浸润作为新诊断的T1期膀胱尿路上皮癌患者进展和转移的预测指标。
J Urol. 2009 Dec;182(6):2625-30. doi: 10.1016/j.juro.2009.08.083. Epub 2009 Oct 17.
6
Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?fascin-1的表达及肿瘤亚分类是否有助于评估T1期膀胱尿路上皮癌的复发和进展风险?
Urol Int. 2008;80(4):413-8. doi: 10.1159/000132700. Epub 2008 Jun 27.
7
Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.经尿道切除术后 T1 期膀胱尿路上皮癌的亚分期对预后的意义。
Am J Surg Pathol. 2012 Mar;36(3):454-61. doi: 10.1097/PAS.0b013e31823dafd3.
8
Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series.通过估计浸润性肿瘤的大小进行亚分期可以改善 pT1 尿路上皮膀胱癌的风险分层-一项大型基于医院的单中心系列研究的评估。
Histopathology. 2011 Oct;59(4):722-32. doi: 10.1111/j.1365-2559.2011.03989.x.
9
Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.在接受手术治疗的局限性上尿路尿路上皮癌患者中,淋巴管浸润与预后不良独立相关。
J Urol. 2007 Dec;178(6):2291-6; discussion 2296. doi: 10.1016/j.juro.2007.08.019. Epub 2007 Oct 22.
10
The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.复发性高危浅表性膀胱肿瘤患者根治性膀胱切除术的最佳时机。
BJU Int. 2004 Dec;94(9):1258-62. doi: 10.1111/j.1464-410X.2004.05228.x.

引用本文的文献

1
The role of tumor-infiltrating lymphocytes and depth of invasion in T1 bladder cancer: a retrospective analysis.肿瘤浸润淋巴细胞在T1期膀胱癌中的作用及浸润深度:一项回顾性分析。
BMC Urol. 2025 May 24;25(1):135. doi: 10.1186/s12894-025-01822-7.
2
Recent Advances in the Classification of Bladder Cancer - Updates from the 5th Edition of the World Health Organization Classification of the Urinary and Male Genital Tumors.膀胱癌分类的最新进展——来自世界卫生组织《泌尿系统及男性生殖器官肿瘤分类》第5版的更新
Bladder Cancer. 2023 Mar 31;9(1):1-14. doi: 10.3233/BLC-220106. eCollection 2023.
3
Combination of Two T1 Substaging Systems (T1a/b/c and T1m/e) Better Predicts Tumor Outcomes in Patients with T1 High Grade Bladder Cancer.
两种T1分期系统(T1a/b/c和T1m/e)的联合能更好地预测T1期高级别膀胱癌患者的肿瘤预后。
Bladder Cancer. 2022 Dec 14;8(4):371-378. doi: 10.3233/BLC-220007. eCollection 2022.
4
The values of HER-2 expression in the non-muscle-invasive bladder cancer: a retrospective clinical study.非肌层浸润性膀胱癌中HER-2表达的价值:一项回顾性临床研究。
Front Oncol. 2023 Nov 27;13:1243118. doi: 10.3389/fonc.2023.1243118. eCollection 2023.
5
Prospective Validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: Results from a Mono-Institutional Confirmatory Analysis in BCG Treated Patients.ROL系统在pT1高级别尿路上皮癌分期中的前瞻性验证:卡介苗治疗患者单中心验证性分析结果
Cancers (Basel). 2023 Feb 1;15(3):934. doi: 10.3390/cancers15030934.
6
The Role of WRAP53 in Cell Homeostasis and Carcinogenesis Onset.WRAP53在细胞稳态和癌症发生起始中的作用
Curr Issues Mol Biol. 2022 Nov 4;44(11):5498-5515. doi: 10.3390/cimb44110372.
7
Bladder Cancer Sample Handling and Reporting: Pathologist's Point of View.膀胱癌样本的处理与报告:病理学家的观点
Front Surg. 2021 Dec 2;8:754741. doi: 10.3389/fsurg.2021.754741. eCollection 2021.
8
T1 Bladder Cancer: Comparison of the Prognostic Impact of Two Substaging Systems on Disease Recurrence and Progression and Suggestion of a Novel Nomogram.T1期膀胱癌:两种亚分期系统对疾病复发和进展的预后影响比较及新型列线图的建议
Front Surg. 2021 Aug 23;8:704902. doi: 10.3389/fsurg.2021.704902. eCollection 2021.
9
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text.加拿大泌尿外科协会非肌层浸润性膀胱癌管理指南 - 全文
Can Urol Assoc J. 2021 Aug;15(8):E424-E460. doi: 10.5489/cuaj.7367.
10
Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR).国际癌症报告协作组织(ICCR)关于泌尿道上皮癌活检和经尿道切除标本报告的数据集建议。
Mod Pathol. 2020 Apr;33(4):700-712. doi: 10.1038/s41379-019-0403-9. Epub 2019 Nov 4.